Oncotarget

Research Papers:

Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patients

Verena Lieb, Katrin Weigelt, Lena Scheinost, Kersten Fischer, Thomas Greither, Marios Marcou, Gerit Theil, Helmut Klocker, Hans-Juergen Holzhausen, Xin Lai, Julio Vera, Arif B. Ekici, Wolfgang Horninger, Paolo Fornara, Bernd Wullich, Helge Taubert _ and Sven Wach

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:10402-10416. https://doi.org/10.18632/oncotarget.23781

Metrics: PDF 807 views  |   HTML 1454 views  |   ?  


Abstract

Verena Lieb1, Katrin Weigelt1, Lena Scheinost1, Kersten Fischer2, Thomas Greither3, Marios Marcou2,3, Gerit Theil2, Helmut Klocker4, Hans-Juergen Holzhausen5, Xin Lai6, Julio Vera6, Arif B. Ekici7, Wolfgang Horninger4, Paolo Fornara2, Bernd Wullich1, Helge Taubert1 and Sven Wach1

1Department of Urology and Pediatric Urology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

2Department of Urology, Martin-Luther-University Halle-Wittenberg, Halle, Germany

3Center for Reproductive Medicine and Andrology, Martin-Luther-University Halle-Wittenberg, Halle, Germany

4Department of Urology, Medical University Innsbruck, Innsbruck, Austria

5Institute of Pathology, Martin Luther University Halle-Wittenberg, Halle, Germany

6Laboratory of Systems Tumor Immunology, Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

7Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

Correspondence to:

Helge Taubert, email: helge.taubert@uk-erlangen.de

Keywords: miR-320 family; diagnosis; prostate cancer; PSA

Abbreviations: PCa: prostate cancer; PSA: prostate specific antigen; OS: overall survival; RPE: radical prostatectomy; BPH: benign prostatic hyperplasia.

Received: July 06, 2017     Accepted: December 23, 2017     Published: December 30, 2017

ABSTRACT

We studied the association of the serum levels of the microRNA family members miR-320a/-b/-c with clinico-pathological data to assess their applicability as diagnostic biomarker in prostate cancer (PCa) patients. The levels of miR-320a/-b/-c in 3 groups were evaluated by qRT-PCR (145 patients with PCa, 31 patients with benign prostatic hyperplasia (BPH) and 19 healthy controls). The levels of the three family members of miR-320 were directly correlated within each group (P < 0.001), but they differed significantly among the three groups (P < 0.001). The serum levels of the miR-320 family members were significantly increased in older patients compared to younger patients (≤ 66 years vs. > 66 years, P ≤ 0.001). In addition, the levels of all three miR-320 family members were significantly different in patients with low tumor stage compared with those with high tumor stage (miR-320a: P = 0.034; miR-320b: P = 0.006; miR-320c: P = 0.007) and in patients with low serum PSA compared with those with high serum PSA (≤ 4 ng vs. > 4 ng; miR-320a: P = 0.003; miR-320b: P = 0.003; miR-320c: P = 0.006). The levels of these miRNAs were inversely correlated with serum PSA levels. Detection in the serum samples of PCa patients with or without PSA relapse revealed higher levels of miR-320a/-b/-c in the group without PSA relapse before/after radical prostatectomy than in that with PCa relapse.

In summary, the differences among the PCa/BPH/healthy control groups with respect to miR-320a/-b/-c levels in conjunction with higher levels in patients without a PSA relapse than in those with a relapse suggest the diagnostic potential of these miRNA-320 family members in PCa patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 23781